| Darunavir boosted with ritonavir (DRV/r) paired with abacavir and lamivudine (ABC/3TC) is considered to be an effective and tolerable regimen for antiretroviral treatment-experienced HIV populations, despite little research supporting its use. |
| When assessed against ABC/3TC paired with other protease inhibitors, ABC/3TC + DRV/r is a comparably effective regimen for achieving virologic suppression in a real-world clinical setting. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.